The company has announced that planning approval has been granted to build its new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings as general contractor for the Reef Group, who will lease the facility. Global commercial launch capacity for obe-cel will initially be provided by the existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult facility, and will then move to the new facility which will allow for GMP capacity for ~2,000 batches a year initially, with scope to expand.
This is the LAST TIME you will see $BIIB this low. Did you see that $48 million BUY yesterday? We could close WELL above $305 today. Yesterday I said ALL savy biotech traders of stocks like $NOVN $PROG $VXRT $BIVI $EVFM $GBS $CLSN $PTGX $ANVS $SAVA $AUTL $NNVC $ENZN $DRNA $PULM $KMPH $APTX $EOLS $RNLX $VKTX $ORPH $APTO $GLTO $HTBX $FMTX $EQ $VRTX $SYN $CAPA $KLDO $TARS $INZY $FLGT $CVAC $XFOR $ACRS $SANA $JNJ $MRK $MRNA $REGN $LLY etc should be loading $BIIB with both hands. I hope they listened. The trend is BULLISH again. If u can't tell. NEW ANALYST Neddham initiated a BUY coverage Yesterday with a target price of $400! $400 is kinda low to me but at least it's better than where $BIIB is now! Free money 💰 imo.
L
Summary why I am long and I do not care when they put the price down like yesterday: 1. Better Tech. The key differentiating feature of Autolus' CAT is that fact that it has a very fast off-rate that is at least 100 times faster than competitor CD19 binders (Figure 2). This means that AUTO1 CAR-T cells are able to kill target cancer cells by contacting them for a much shorter period of time, as a normal T-cell would. 2. Orphan Drug FDA designation + PIM designation 3. Lizenz Agreement with Moderna 4. Great promising early result. 100% complete remission 5. Enough funding 6. New partnership any time possible 7. Early buyout in 2022 possible 8. Still flying under the radar 9. Expecting more institutional investors coming in 10. Expecting further great data EOY and in 2022
AUTO1 is uniquely positioned among CD19-targeted CAR-T products due to its fast off-rate kinetics.
AUTO1 is uniquely positioned among CD19-targeted CAR-T products due to its fast off-rate kinetics.
seekingalpha.com
R
Bill don't you ever have a positive thing to say about the company?
J
The company has announced that it has received PIM designation from the UK's MHRA for AUTO1 in R/R adult ALL.
R
Long term Moderna holder. Opened a position in Autolus today. I could see this being aquired by Moderna in the future.
J
The company announced an agreement with MRNA, granting them an exclusive license to develop and commercialise mRNA therapeutics incorporating proprietary binders for up to four IO targets. AUTL would be eligible to receive an upfront payment for each target licensed and development and commercial milestone payments for each product successfully commercialised. In addition, entitled to receive royalties on net sales of all products commercialised under the agreement.
Look into $AUTL, Moderna signed a licensing agreement to use thier technology. Market cap is around 500M. Could be a good investment. I just threw 2K at AUTL.
S
Moderna may acquire AUTL !!
J
Backed by Moderna, unreal.
A
Going to double my position again
B
Small morning sell off. Time to rebound!!! Good way to start off a morning!
B
$12 EOD price target. Huge news!
t
these new therapies are the future of medicine. I know, I had lymphoma and got one of these new therapies and am doing very well
A
Time to align the moving averages back in line….
g
Fellow moderna shareholder here - prior to covid too- I’m buying autl at the open.
1. Better Tech. The key differentiating feature of Autolus' CAT is that fact that it has a very fast off-rate that is at least 100 times faster than competitor CD19 binders (Figure 2). This means that AUTO1 CAR-T cells are able to kill target cancer cells by contacting them for a much shorter period of time, as a normal T-cell would.
2. Orphan Drug FDA designation + PIM designation
3. Lizenz Agreement with Moderna
4. Great promising early result. 100% complete remission
5. Enough funding
6. New partnership any time possible
7. Early buyout in 2022 possible
8. Still flying under the radar
9. Expecting more institutional investors coming in
10. Expecting further great data EOY and in 2022
Feel free to add this list. IMO
Reminder from 2020: https://seekingalpha.com/article/4346557-autolus-highly-undervalued-car-t-company